<DOC>
	<DOC>NCT00247026</DOC>
	<brief_summary>To determine the clinical effects of coenzyme Q10 and Curcumin in improving the cytopenias of patients with myelodysplastic syndromes. we propose to explore the efficacy of the natural compounds curcumin and CoQ10 in MDS because these two agents possess many of the effects that are desirable in MDS.</brief_summary>
	<brief_title>The Efficacy of Coenzyme Q10 And Curcumin in Patients With Myelodysplastic Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Curcumin</mesh_term>
	<mesh_term>Coenzyme Q10</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>MDS patients with RA, RARS or RAEB will be eligible for treatment with CoQ10 as long as their IPSS score â‰¤ 1.5. Pregnant women and nursing women will be excluded. History of clinically significant liver or kidney disease. ECOG&gt;2 IPSS score &gt;1.5 Poorly controlled diabetes mellitus, hypertension, or other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to the protocol.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>myelodysplasia</keyword>
	<keyword>curcumin</keyword>
	<keyword>coenzyme Q10</keyword>
	<keyword>cytopenia</keyword>
</DOC>